Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ValiRx plc ( (GB:VAL) ) has provided an announcement.
ValiRx PLC, through its subsidiary Inaphaea BioLabs, has entered into strategic agreements with Dominion Biotech Ltd and Cellomatics Biosciences Ltd to enhance its cancer therapeutics offerings. The collaboration with Dominion allows both companies to co-market services using their combined patient-derived cancer (PDC) biobanks, while the agreement with Cellomatics focuses on evaluating colorectal cancer PDCs for potential commercial services. These partnerships aim to expand market penetration and improve access to diverse cancer models, potentially accelerating the development of effective cancer therapies.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, aiming to accelerate the translation of innovative science into impactful medicines. The company provides a framework for rapid translation of novel drug candidates into clinical development, leveraging its expertise in research and drug development to streamline and reduce the cost of the drug development process. ValiRx collaborates with various disciplines to advance science and partners with investors for further clinical development and commercialization.
YTD Price Performance: -39.10%
Average Trading Volume: 2,488,993
Technical Sentiment Signal: Buy
Current Market Cap: £1.78M
For an in-depth examination of VAL stock, go to TipRanks’ Stock Analysis page.